1. bookVolume 58 (2020): Issue 1 (March 2020)
Journal Details
License
Format
Journal
First Published
30 Mar 2015
Publication timeframe
4 times per year
Languages
English
Copyright
© 2020 Sciendo

Immunosuppressive treatment for peripheral neuropathies in Sjogren’s syndrome – a systematic review

Published Online: 03 Mar 2020
Page range: 5 - 12
Received: 01 Aug 2019
Journal Details
License
Format
Journal
First Published
30 Mar 2015
Publication timeframe
4 times per year
Languages
English
Copyright
© 2020 Sciendo
Abstract

Background. Sjogren’s syndrome (SS) is among the most frequent autoimmune diseases and one of its most severe extraglandular manifestations is peripheral neuropathy. There is no consensus about peripheral neuropathy treatment in SS. Our aim is to identify studies proving the efficiency of immunosuppressive treatment on peripheral neuropathies in SS.

Methods. The search was conducted on the PubMed (MEDLINE) database. Studies with patients diagnosed with SS and peripheral neuropathy were included. Treatment with one of the following was among inclusion criteria: glucocorticoids (GC), rituximab (RTX), azathioprine (AZA), mycophenolic acid (MMF), cyclophosphamide (CP), methotrexate (MTX), plasmapheresis or iv immunoglobulins (IV IG).

Results. A total of 116 results were found and abstracts were examined. 103 papers were excluded, and the remaining 13 papers were analyzed. They were 3 case series and 10 case reports, retrospective, totalizing 62 patients of which 22 (35.5%) received IV IG, 8 (13%) received RTX, 7 (11%) CP, and 5 (8%) received only GC. Drug associations containing corticosteroids were frequent. Of those 22 treated with IV IG, 18 patients improved (82%), and 4 stabilized (18%).

IV IG was useful in sensory, motor and sensorimotor neuropathies. CP had good results in mononeuritis multiplex, while autonomic neuropathies responded well to GC or RTX. AZA, RTX, MTX, MMF or plasmapheresis were not used alone. Follow-up periods were heterogenous and the evaluation of the neuropathy was not systematic.

Conclusion. There is only low level evidence (retrospective case reports and case series). In most cases, IV IG treatment in patients with peripheral neuropathies and SS resulted in clinical improvement, while other therapies, such as RTX, corticosteroids and CP proved to be useful in a handful of cases.

Keywords

1. FISHER B.A., BROWN R.M., BOWMAN S.J., BARONE F. A review of salivary gland histopathology in primary Sjögren’s syndrome with a focus on its potential as a clinical trials biomarker. Ann Rheum Dis. 2015; 74:1645–50.Search in Google Scholar

2. CHERIF E., BOUKHRIS I., HAJJI R., HASSINE LB., AZZABI S., KECHAOU I. et al. Extra-glandular manifestations of primary Sjögren’s syndrome. Eur J Intern Med. 2013; 24:e119.Search in Google Scholar

3. ATTWOOD W., POSER CM. Neurologic complications of Sjogren’s syndrome. Neurology. 1961; 11:1034–41.Search in Google Scholar

4. PAVLAKIS P.P., ALEXOPOULOS H., KOSMIDIS M.L., MAMALI I., MOUTSOPOULOS H.M., TZIOUFAS A.G. et al. Peripheral neuropathies in Sjögren’s syndrome: A critical update on clinical features and pathogenetic mechanisms. J Autoimmun. 2012; 39:27–33.Search in Google Scholar

5. MARGARETTEN M. Neurological manifestations of primary Sjögren’s syndrome. Reumatologia. 2018; 56:99–105.Search in Google Scholar

6. DELALANDE S., DE SEZE J., FAUCHAIS A.-L., HACHULLA E., STOJKOVIC T., FERRIBY D. et al. Neurologic manifestations in primary Sjögren syndrome. Medicine (Baltimore). 2004; 83:280–91.Search in Google Scholar

7. MOROZUMI S., KAWAGASHIRA Y., IIJIMA M., KOIKE H., HATTORI N., KATSUNO M. et al. Intravenous immunoglobulin treatment for painful sensory neuropathy associated with Sjögren’s syndrome. J Neurol Sci. 2009; 279:57–61.Search in Google Scholar

8. LEVY Y., UZIEL Y., ZANDMAN G.G., AMITAL H., SHERER Y., LANGEVITZ P. et al. Intravenous immunoglobulins in peripheral neuropathy associated with vasculitis. Ann Rheum Dis. 2003; 62:1221–3.Search in Google Scholar

9. MOCHIZUKI H., KAMAKURA K., MASAKI T., HIRATA A., NAKAMURA R., MOTOYOSHI K. Motor dominant neuropathy in Sjoegren’s syndrome: Report of two cases. Intern Med. 2008; 41:142–6.Search in Google Scholar

10. FONT J., RAMOS-CASALS M., DE LA RED G., POU A., CASANOVA A., GARCIA-CARRASCO M. et al. Pure sensory neuropathy in primary Sjögren’s syndrome. Longterm prospective followup and review of the literature. J Rheumatol. 2003; 30:1552–7.Search in Google Scholar

11. RIST S., SELLAM J., HACHULLA E., SORDET C., PUECHAL X., HATRON P. et al. Experience of intravenous immunoglobulin therapy in neuropathy associated with primary Sjögren’s syndrome: A national multicentric retrospective study. Arthritis Care Res (Hoboken). 2011; 63:1339–44.Search in Google Scholar

12. PERTOVAARA M., KORPELA M. Sustained response to rituximab in a patient with Sjögren´s syndrome and severe refractory polyneuropathy. Clin Exp Rheumatol. 2012; 30:808.Search in Google Scholar

13. MEKINIAN A., RAVAUD P., HATRON P.Y., LARROCHE C., LEONE J., GOMBERT B. et al. Efficacy of rituximab in primary Sjogren’s syndrome with peripheral nervous system involvement: results from the AIR registry. Ann Rheum Dis. 2012; 71:84–7.Search in Google Scholar

14. MIN J.K., PARK K.S., YU W.J., LEE Y.S., PARK S.M., PARK S.H. et al. Systemic mononuclear inflammatory vasculopathy associated with Sjögren’s syndrome in a patient with primary biliary cirrhosis. Korean J Intern Med. 2000; 15:89–92.Search in Google Scholar

15. SHIMOYAMA M., OHTAHARA A., OKAMURA T., WATANABE M., FUJIMOTO Y., TESHIMA S. et al. Isolated autonomic cardiovascular neuropathy in a patient with primary Sjögren syndrome: a case of successful treatment with glucocorticoid. Am J Med Sci. 2002; 324:170–2.Search in Google Scholar

16. DUPOND J.L., GIL H., DE WAZIERES B. Five-year efficacy of intravenous gammaglobulin to treat dysautonomia in Sjögren’s syndrome. Am J Med. 1999; 106:125.Search in Google Scholar

17. PASCUAL J., CID C., BERCIANO J. High-dose i.v. immunoglobulin for peripheral neuropathy associated with Sjögren’s syndrome. Neurology. 1998; 51:650–1.Search in Google Scholar

18. KIZAWA M., MORI K., IIJIMA M., KOIKE H., HATTORI N., SOBUE G. Intravenous immunoglobulin treatment in painful sensory neuropathy without sensory ataxia associated with Sjögren’s syndrome. J Neurol Neurosurg Psychiatry. 2006; 77:967–9.Search in Google Scholar

19. MOLINA J.A., BENITO-LEÓN J., BERMEJO F., JIMÉNEZ-JIMÉNEZ F.J., OLIVÁN J. Intravenous immunoglobulin therapy in sensory neuropathy associated with Sjögren’s syndrome. J Neurol Neurosurg Psychiatry. 1996; 60:699.Search in Google Scholar

20. TAKAHASHI Y., TAKATA T., HOSHINO M., SAKURAI M., KANAZAWA I. Benefit of IVIG for long-standing ataxic sensory neuronopathy with Sjögren’s syndrome. IV immunoglobulin. Neurology. 2003; 60:503–5.Search in Google Scholar

21. MORI K., IIJIMA M., KOIKE H., HATTORI N., TANAKA F., WATANABE H. et al. The wide spectrum of clinical manifestations in Sjögren’s syndrome-associated neuropathy. Brain. 2005; 128:2518–34.Search in Google Scholar

22. GORSON K.C., NATARAJAN N., ROPPER A.H., WEINSTEIN R. Rituximab treatment in patients with IVIg-dependent immune polyneuropathy: A prospective pilot trial. Muscle Nerve. 2007; 35:66–9.Search in Google Scholar

23. BOTEZ S.A., HERRMANN D.N. Prolonged remission of a demyelinating neuropathy in a patient with lymphoma and Sjögren’s syndrome after Rituximab therapy. J Clin Neuromuscul Dis. 2010; 11:127–31.Search in Google Scholar

24. MEIJER J.M., MEINERS P.M., VISSINK A., SPIJKERVET F.K.L., ABDULAHAD W., KAMMINGA N. et al. Effectiveness of rituximab treatment in primary Sjögren’s syndrome: A randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2010; 62:960–8.Search in Google Scholar

25. VOULGARELIS M., GIANNOULI S., TZIOUFAS A.G., MOUTSOPOULOS H.M. Long term remission of Sjogren’s syndrome associated aggressive B cell non-Hodgkin’s lymphomas following combined B cell depletion therapy and CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone). Ann Rheum Dis. 2006; 65:1033–7.Search in Google Scholar

26. MOHER D., LIBERATI A., TETZLAFF J., ALTMAN D.G., GROUP T.P. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA Statement. PLoS Med. 2009; 6:e1000097.Search in Google Scholar

27. WAKASUGI D., KATO T., GONO T., ITO E., NODERA H., KAWAGUCHI Y. et al. Extreme efficacy of intravenous immunoglobulin therapy for severe burning pain in a patient with small fiber neuropathy associated with primary Sjögren’s syndrome. Mod Rheumatol. 2009; 19:437–40.Search in Google Scholar

Plan your remote conference with Sciendo